Molecular Templates Inc (MTEM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Molecular Templates Inc (MTEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8059
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Molecular Templates Inc (MTI), formerly Threshold Pharmaceuticals Inc, is a clinical-stage oncology company that discovers and develops biologic therapeutics for cancer. The company’s pipeline products include MT-3724, MT-4019, MT-5111, MT-5050 and MT-6868. Its lead product MT-3724, a fusion protein, is designed for the treatment of Non-Hodgkin Lymphoma; and MT-4019 is used for the treatment of multiple myeloma. The company also develops Engineered Toxin Bodies (ETBs) for the treatment of breast cancer, melanoma and allogeneic stem cell transplantation. The company develops ETBs for various targets including CD20, CD38, HER2, and PD-L1. MTI is headquartered in Austin, Texas, the US.

Molecular Templates Inc (MTEM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Molecular Templates Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Molecular Templates Raises USD40 million in Venture Financing 12
Molecular Templates Raises Additional USD3.5 Million in Series C Financing 14
Molecular Templates Raises USD7 Million in Venture Financing 15
Molecular Templates Raises US$8.5 Million In Series C Financing 16
Partnerships 17
Molecular Templates Enters into Agreement with Takeda Pharma 17
AbCheck and Molecular Templates Enter into Agreement 18
Takeda Pharma Enters into Research Agreement with Molecular Templates 19
Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 20
Molecular Templates Enters into Agreement with Veristat 21
Merger 22
Molecular Templates Merges with Threshold Pharma 22
Equity Offering 24
Molecular Templates Raises USD52 Million in Public Offering of Shares 24
Molecular Templates Files Registration Statement to Raise Funds through Public Offering of Shares 26
Molecular Templates Raises USD20 million in Equity Financing 27
Acquisition 28
Threshold Pharma Acquires Molecular Templates 28
Molecular Templates Inc – Key Competitors 30
Molecular Templates Inc – Key Employees 31
Molecular Templates Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Strategy And Business Planning 33
Sep 21, 2018: Takeda and Molecular Templates partner on protein-based cancer therapy 33
Financial Announcements 34
Aug 09, 2018: Molecular Templates reports second quarter 2018 financial results 34
May 14, 2018: Molecular Templates Announces First Quarter 2018 Financial Results 36
Mar 28, 2018: Molecular Templates Announces Fourth Quarter 2017 Financial Results 37
Nov 14, 2017: Molecular Templates Reports Third Quarter 2017 Financial Results 39
Corporate Communications 41
Nov 14, 2017: Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer 41
Product News 43
10/24/2017: OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 43
Product Approvals 44
Jul 09, 2018: OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC) 44
Apr 18, 2018: OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors 45
Clinical Trials 46
Mar 15, 2018: New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research Annual Meeting 2018 46
Oct 29, 2017: OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 47
Jun 13, 2017: Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab 48
Mar 30, 2017: Molecular Templates Announces Presentation on MT-4019 at the 2017 American Association for Cancer Research Annual Meeting 49
Other Significant Developments 50
Jan 05, 2018: Molecular Templates Provides Corporate Update and Outlines 2018 Milestones 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Molecular Templates Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Molecular Templates Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Molecular Templates Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Templates Raises USD40 million in Venture Financing 12
Molecular Templates Raises Additional USD3.5 Million in Series C Financing 14
Molecular Templates Raises USD7 Million in Venture Financing 15
Molecular Templates Raises US$8.5 Million In Series C Financing 16
Molecular Templates Enters into Agreement with Takeda Pharma 17
AbCheck and Molecular Templates Enter into Agreement 18
Takeda Pharma Enters into Research Agreement with Molecular Templates 19
Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 20
Molecular Templates Enters into Agreement with Veristat 21
Molecular Templates Merges with Threshold Pharma 22
Molecular Templates Raises USD52 Million in Public Offering of Shares 24
Molecular Templates Files Registration Statement to Raise Funds through Public Offering of Shares 26
Molecular Templates Raises USD20 million in Equity Financing 27
Threshold Pharma Acquires Molecular Templates 28
Molecular Templates Inc, Key Competitors 30
Molecular Templates Inc, Key Employees 31
Molecular Templates Inc, Subsidiaries 32

List of Figures
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Molecular Templates Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Molecular Templates Inc (MTEM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Parkway Pantai Ltd:企業の戦略的SWOT分析
    Parkway Pantai Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Torrent Power Limited:発電所・企業SWOT分析
    Torrent Power Limited - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • Humanwell Healthcare (Group) Co Ltd (600079)-医療機器分野:企業M&A・提携分析
    Summary Humanwell Healthcare (Group) Co Ltd (Humanwell), formerly Wuhan Humanwell Hi-Tech Industry Co Ltd is a pharmaceutical company that offers generic products. The company offers pharmaceutical, medical instrument and reproductive health care products and technologies. It provides anesthetics, b …
  • HTG Molecular Diagnostics Inc (HTGM):製薬・医療:M&Aディール及び事業提携情報
    Summary HTG Molecular Diagnostics Inc (HTG) is a technology company that provides molecular technology solutions. The company provides products such as HTG edge system, HTG edgeseq reagents and HTG edgeseq immuno-oncology biomarker panel assay, among others. It develops assays and reagent systems th …
  • BioChain Institute Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioChain Institute Inc (BioChain) is a medical device company that designs, develops and markets diagnostic products. The company offers processed bio-sample products and analysis services used in translational medicine, companion diagnostics, and clinical product research and development. I …
  • bluebird bio Inc (BLUE):企業の財務・戦略的SWOT分析
    bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • DesignMedix Inc-製薬・医療分野:企業M&A・提携分析
    Summary DesignMedix Inc (DesignMedix) is a biotechnology company that develop drugs to overcome drug resistance in multiple diseases including malaria and diarrhea. The company focuses on the development of malaria cure drugs, malaria preventive drugs and anti-bacterial drugs. Its malaria cure drugs …
  • 88 Energy Ltd (88E):石油・ガス:M&Aディール及び事業提携情報
    Summary 88 Energy Ltd (88 Energy), formerly Tangiers Petroleum Ltd, is an exploration and production company that develops oil-rich provinces. The company offers discovery, exploration and development of onshore oil projects. It has oil and gas assets in Morocco and Australia. 88 Energy’s Morocco pr …
  • Verde Science Inc-石油・ガス分野:企業M&A・提携分析
    Summary Verde Science Inc (Verde Science), formerly Rango Energy Inc is a medical technology company that offers bioprocess solutions. The company offers research and development services with expertise in bioprocess technology, molecular virology and immunology, nanotechnology, pharmacology and med …
  • Oil States International, Inc.:企業の戦略・SWOT・財務分析
    Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Cryo-Cell International Inc (CCEL):企業の財務・戦略的SWOT分析
    Summary Cryo-Cell International Inc (Cryo-Cell) is a cord blood bank service provider. The company offers biotechnology services, collection and preservation of umbilical cord blood stem cells for family use. It provides services such as cord blood banking, cord tissue banking, cord blood and tissue …
  • Ceapro Inc (CZO):製薬・医療:M&Aディール及び事業提携情報
    Summary Ceapro Inc (Ceapro) is a biotechnology company which develops proprietary extraction technologies for use in the production of extracts and active ingredients from oats and other renewable plant resources. The company’s extracts are also used in nutraceutical, cosmeceutical, and therapeutics …
  • Galaxy Entertainment Group Ltd
    Galaxy Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Galaxy Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Blueknight Energy Partners LP:企業のM&A・事業提携・投資動向
    Blueknight Energy Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Blueknight Energy Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Hill-Rom Holdings, Inc.:戦略・SWOT・企業財務分析
    Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Puccino’s Worldwide Ltd:企業の戦略・SWOT・財務情報
    Puccino's Worldwide Ltd - Strategy, SWOT and Corporate Finance Report Summary Puccino's Worldwide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • OraSure Technologies Inc (OSUR)-製薬・医療分野:企業M&A・提携分析
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; and ant …
  • M.C. Dean Inc:企業の戦略・SWOT・財務情報
    M.C. Dean Inc - Strategy, SWOT and Corporate Finance Report Summary M.C. Dean Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Havells India Ltd (HAVELLS)-エネルギー分野:企業M&A・提携分析
    Summary Havells India Limited (Havells) is a fast moving electrical goods (FMEG) company that carries out the design, production and distribution of a range of world class industrial and consumer electrical products. Its products include building circuit protection products, capacitors, cables and w …
  • Vivus Inc (VVUS):製薬・医療:M&Aディール及び事業提携情報
    Summary Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's marketed products include, Qsymia (phentermine and topiramate extended-release), indic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆